The oligonucleotide synthesis, modification and purification services market is projected to grow at an annualized rate of ~10%, till 2030
Roots Analysis has done a detailedstudy on “Oligonucleotide Synthesis, Modification and PurificationServices Market: Focus onResearch, Diagnostic and Therapeutic Applications, 2020-2030” covering key aspects of theindustry’s evolution and identifying potential future growth opportunities.
To order this 300+ page report, which features 140+ figuresand 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
Key Market Insights
§ More than 80companies currently claim to offer manufacturing related services, at differentscales of operations, for a variety of oligonucleotide-based products
§ A wide range ofservices related to the synthesis, modification and purification ofoligonucleotides, are currently offered within a fragmented service providerlandscape that is mostly concentrated in the developed geographies
§ In order to cater tothe growing needs of clients / sponsors, companies have established presenceacross different regions; the US and some European nations have emerged ascurrent hubs for oligonucleotide production
§ Players involved in this domain are steadily expanding theircapabilities in order to enhance their respective service portfolios andthereby, achieve an edge over competing firms
§ Service providers are activelyinvesting in expansion projects to upgrade existing capabilities and capacity;several partnerships, mostly focused on offering manufacturing and supplyservices, have been forged
§ Over the past fewyears, more than 270 trials of oligonucleotide-based interventions, acrossvarious phases of development and to treat a diverse range of diseases, havebeen registered across different centers worldwide
§ Most of the global, annual oligonucleotide manufacturing capacitybelongs to established service providers, accounting for over 80% of availablecapacity across various geographies
§ The demand formanufacturing of oligonucleotide-based products is expected to increase in thecoming years; we believe that the stakeholders may have to expand theirrespective capacities to ensure consistent supply
§ We expect oligonucleotide-based drug developers to continue to outsourcetheir manufacturing operations in the short to mid-term; service-based revenuesare estimated to grow at an annualized rate of more than 10%
§ In the long-term, theprojected opportunity is anticipated to be well distributed across varioustherapeutic areas, scales of operation and across companies of different sizes
For more information, please visit https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
Table of Contents
1.1. Scope ofthe Report
1.2. ResearchMethodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Oligonucleotide-based Products
3.3. Types of Oligonucleotides
3.3.1. Antisense Oligonucleotides
3.3.2. Aptamers
3.3.3. miRNA
3.3.4. shRNA
3.3.5. siRNA
3.3.6. Other Oligonucleotides
3.4. Custom Synthesis of Oligonucleotides
3.4.1. Process Development and Characterization
3.4.2. Analytical Method Development
3.4.3. Method Validation and Testing
3.4.4. Quality Control and Quality Assurance
3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides
3.5. Chemical Modification of Oligonucleotides
3.5.1. Backbone Modification
3.5.2. Sugar Ring Modification
3.6. Purification of Oligonucleotides
3.6.1. Desalting
3.6.2. Cartridge Purification
3.6.3. Polyacrylamide Gel Electrophoresis (PAGE)
3.6.4. High Performance Liquid Chromatography (HPLC)
3.7. Outsourcing Oligonucleotide Manufacturing
3.7.1. Need for Outsourcing
3.7.2. Commonly Outsourced Operations
3.7.3. Advantages of Outsourcing Manufacturing Operations
3.7.4. Guidelines for Selecting a Service Provider
3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
3.9. Recent Developments and Upcoming Trends
4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCHAND DIAGNOSTIC APPLICATIONS)
4.1. Chapter Overview
4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall MarketLandscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Regulatory Accreditations /Certifications
4.2.7. Analysis by Type of Oligonucleotide Manufactured
4.2.8. Analysis by Type of Offering
4.2.9. Analysis by Type of Manufacturing Service(s) Offered
4.2.10. Analysis by Type of Modification(s) Offered
4.2.11. Analysis by Type of Purification Method(s)Used
4.2.12. Analysis by Compliance to cGMP Standards
5. MARKETLANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
5.1. Chapter Overview
5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Regulatory Accreditations / Certifications
5.2.7. Analysis by Type of Oligonucleotide Manufactured
5.2.8. Analysis by Type of Offering
5.2.9. Analysis by Type of Manufacturing Service(s) Offered
5.2.10. Analysis by Type of Modification(s) Offered
5.2.11. Analysis by Type of Purification Method(s) Used
5.2.12. Analysis by Compliance to cGMP Standards
6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDEMANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Company Competitiveness Analysis: Oligonucleotide ManufacturersFocused on Research and Diagnostic Applications
6.3.1. Oligonucleotide Manufacturers in North America
6.3.2. Oligonucleotide Manufacturers in Europe
6.3.3. Oligonucleotide Manufacturers in Asia-Pacific
7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDEMANUFACTURERS (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Company Competitiveness Analysis: Oligonucleotide ManufacturersFocused on Therapeutic Applications
7.3.1. Oligonucleotide Manufacturers in North America
7.3.2. Oligonucleotide Manufacturers in Europe
7.3.3. Oligonucleotide Manufacturers in Asia-Pacific
8. COMPANYPROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
8.1. Chapter Overview
8.2. Ajinomoto Bio-Pharma Services
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Manufacturing Facilities and Capabilities
8.2.4. Recent Developments and Future Outlook
8.3. Integrated DNA Technologies
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Manufacturing Facilities and Capabilities
8.3.4. Recent Developments and Future Outlook
8.4. Kaneka Eurogentec
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Manufacturing Facilities and Capabilities
8.4.4. Recent Developments and Future Outlook
8.5. LGC Biosearch Technologies
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Manufacturing Facilities and Capabilities
8.5.4. Recent Developments and Future Outlook
8.6. Microsynth
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Manufacturing Facilities and Capabilities
8.6.4. Recent Developments and Future Outlook
8.7. Sigma Aldrich
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Service Portfolio
8.7.4. Manufacturing Facilities and Capabilities
8.7.5. Recent Developments and Future Outlook
8.8. Thermo Fisher Scientific
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Service Portfolio
8.8.4. Manufacturing Facilities and Capabilities
8.8.5. Recent Developments and Future Outlook
9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTICAPPLICATIONS)
9.1. Chapter Overview
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
9.2.5. Recent Developments and Future Outlook
9.3. BioSpring
9.3.1. Company Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities
9.3.4. Recent Developments and Future Outlook
9.4. CordenPharma
9.4.1. Company Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities
9.4.4. Recent Developments and Future Outlook
9.5. Nitto Denko Avecia
9.5.1. Company Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities
9.5.4. Recent Developments and Future Outlook
9.6. TriLink Biotechnologies
9.6.1. Company Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities
9.6.4. Recent Developments and Future Outlook
10. PARTNERSHIPS AND COLLABORATIONS
10.2. PartnershipModels
10.3. OligonucleotideManufacturers: Recent Partnerships and Collaborations
10.3.1. Analysis byYear of Partnership
10.3.2. Analysis byType of Partnership
10.3.3. Analysis byType of Partner
10.3.4. Most ActivePlayers: Analysis by Number of Partnerships
10.3.5. GeographicalAnalysis
10.3.5.1. Most Active Players: Geographical Distribution byNumber of Partnerships
10.3.5.2. Intercontinental and Intracontinental Agreements
11. RECENT EXPANSIONS
11.1. Chapter Overview
11.2. Oligonucleotide Manufacturers: Recent Expansions
11.2.1. Analysis by Year of Expansion
11.2.2. Analysis by Type of Expansion
11.2.3. Analysis by Application
11.2.4. Analysis by Location of Facility
11.2.5. Analysis by Expanded Facility Area
11.2.6. Analysis by Expanded Scale of Operation
11.3.7. Most Active Players: Analysis by Number of Expansions
11.3.8. Geographical Analysis
11.3.8.1. Continent-wiseDistribution
11.3.8.2. Country-wiseDistribution
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Clinical Trial Analysis: Oligonucleotide-based Drug Products
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Oligonucleotide
12.3.4. Analysis by Type of Oligonucleotide and Phase of Development
12.3.5. Analysis by Trial Recruitment Status
12.3.6. Analysis by Trial Focus Area
12.3.7. Analysis by Target Therapeutic Area
12.3.8. Geographical Analysis by Number of Clinical Trials
12.3.9. Geographical Analysis by Enrolled Patient Population
12.3.10. Analysis by Type of Sponsor/ Collaborator
12.3.11. Most Active Players:Analysis by Number of Registered Trials
13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Oligonucleotide Manufacturers: Global, Annual Capacity
13.3.1. Analysis by Size of Manufacturer
13.3.2. Analysis by Scale of Operation
13.3.3. Analysis by Location of Manufacturing Facility
14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Oligonucleotide Manufacturing
14.3.1. Global Commercial Demand for Oligonucleotide Manufacturing
14.3.1.1. Analysis by Type ofOligonucleotide
14.3.1.2. Analysis by TargetTherapeutic Area
14.3.1.3. Analysis by Geography
14.3.2. Global Clinical Demand for Oligonucleotide Manufacturing
14.3.2.1. Analysis by Type ofOligonucleotide
14.3.2.2. Analysis by Phase ofDevelopment
14.3.2.3. Analysis by TargetTherapeutic Area
14.3.2.4. Analysis by Geography
14.4. Demand and Supply Analysis
14.4.1. Demand and Supply Analysis (Scenario 1)
14.4.2. Demand and Supply Analysis (Scenario 2)
14.4.3. Demand and Supply Analysis (Scenario 3)
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Forecast Methodology
15.3. Overall Oligonucleotide Manufacturing Market, 2020-2030
15.4. Oligonucleotide Manufacturing Market,2020-2030: Analysis by Type of Manufacturing
15.4.1. Custom Oligonucleotide Manufacturing Market, 2020-2030
15.4.2. Large-scale Oligonucleotide ManufacturingMarket, 2020-2030
15.4.2.1 Oligonucleotide Manufacturing Market,2020-2030: Analysis by Type of Oligonucleotide Manufactured
15.4.2.1.1. Oligonucleotide Manufacturing Market for AntisenseOligonucleotides, 2020-2030
15.4.2.1.2. Oligonucleotide Manufacturing Market for miRNA, 2020-2030
15.4.2.1.3. OligonucleotideManufacturing Market for shRNA, 2020-2030
15.4.2.1.4. Oligonucleotide Manufacturing Market for siRNA, 2020-2030
15.4.2.1.5. Oligonucleotide Manufacturing Market for OtherOligonucleotides, 2020-2030
15.4.2.2. Oligonucleotide Manufacturing Market,2020-2030: Analysis by Scale of Operation
15.4.2.2.1. Oligonucleotide Manufacturing Market for Clinical ScaleOperations, 2020-2030
15.4.2.2.2. Oligonucleotide Manufacturing Market for Commercial ScaleOperations, 2020-2030
15.4.2.3. Oligonucleotide Manufacturing Market, 2020-2030: Analysis byPurpose of Production
15.4.2.3.1. OligonucleotideManufacturing Market for In-House Operations, 2020-2030
15.4.2.3.2. OligonucleotideManufacturing Market for Outsourced Operations, 2020-2030
15.4.2.4. Oligonucleotide Manufacturing Market,2020-2030: Analysis by Target Therapeutic Area
15.4.2.4.1. Oligonucleotide Manufacturing Market for AutoimmuneDisorders, 2020-2030
15.4.2.4.2. OligonucleotideManufacturing Market for Cardiovascular Disorders, 2020-2030
15.4.2.4.3. OligonucleotideManufacturing Market for Genetic Disorders, 2020-2030
15.4.2.4.4. OligonucleotideManufacturing Market for Infectious Diseases, 2020-2030
15.4.2.4.5. Oligonucleotide Manufacturing Market for MetabolicDisorders, 2020-2030
15.4.2.4.6. OligonucleotideManufacturing Market for Neuromuscular Disorders, 2020-2030
15.4.2.4.7. Oligonucleotide Manufacturing Market for OncologicalDisorders, 2020-2030
15.4.2.4.8. Oligonucleotide Manufacturing Market for OphthalmicDisorders, 2020-2030
15.4.2.4.9. Oligonucleotide Manufacturing Market for Other TherapeuticAreas, 2020-2030
15.4.2.5. Oligonucleotide Manufacturing Market,2020-2030: Analysis by Size of Manufacturer
15.4.2.5.1. Oligonucleotide Manufacturing Market for Small Companies,2020-2030
15.4.2.5.2. Oligonucleotide Manufacturing Market for Mid-sizedCompanies, 2020-2030
15.4.2.5.3. Oligonucleotide Manufacturing Market for Large Companies,2020-2030
15.4.2.6. Oligonucleotide Manufacturing Market,2020-2030: Analysis by Geography
15.4.2.6.1. Oligonucleotide Manufacturing Market in North America,2020-2030
15.4.2.6.2. Oligonucleotide Manufacturing Market in Europe, 2020-2030
15.4.2.6.3. Oligonucleotide Manufacturing Market in Asia-Pacific andRest of the World, 2020-2030
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors
17. SURVEY ANALYSIS
17.1. Chapter Overview
17.2. Overview of Respondents
17.2.1. Seniority Level of Respondents
17.3. Survey Insights
17.3.1. Type of Offering
17.3.2. Application
17.3.3. Manufacturing Capacity
17.3.4. Location of Manufacturing Facilities
17.3.5. Extent of Outsourcing
17.3.6. Current Market Opportunity
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. BianoScience
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Tobias Pohlmann, Founder and ManagingDirector
18.3. IBA Life Sciences
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer andManaging Director
19. CONCLUDING REMARKS
19.1. Chapter Overview
19.2. Key Takeaways
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
